BioCentury | Sep 21, 2018
Clinical News

Zealand's hypoglycemia candidate meets in second Phase III

...and antidrug antibodies (ADAs) Status: Phase III data Milestone: Complete Phase III (mid-2019) Jaime De Leon Dasiglucagon in rescue pen (zp4207 in rescue pen...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...Duobrii (IDP-118) Moderate to severe plaque psoriasis PDUFA date 6/18/18 Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) Dasiglucagon in rescue pen...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Inc. (NASDAQ:VTVT) Azeliragon Mild AD Ph III STEADFAST data 2018 Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) Dasiglucagon in rescue pen...
BioCentury | Dec 15, 2017
Clinical News

Zealand starts second Phase III of dasiglucagon for severe hypoglycemia

...see BioCentury, July 7 ). Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), Glostrup, Denmark Product: Dasiglucagon in rescue pen (formerly ZP4207 in rescue pen...
...powder form Status: Phase III started Milestone: Phase III data (2Q18); Phase III data (2H18) Chris Lieu dasiglucagon in rescue pen Zealand...
BioCentury | Aug 9, 2017
Financial News

Zealand lists on NASDAQ

...lost DKK4.5 to DKK114 in Copenhagen and gained less than 1% to $17.82 on NASDAQ. Kevin Lehnbeuter Adlyxin dasiglucagon in rescue pen Lantus Lyxumia Soliqua Sanofi Zealand...
BioCentury | Jul 7, 2017
Clinical News

Zealand begins Phase III of dasiglucagon in severe hypoglycemia

...glucagon receptor (GCGR) agonist in 4Q17. Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: Dasiglucagon in rescue pen (formerly ZP4207 in rescue pen...
...I diabetes Endpoint: Immunogenicity and safety Status: Phase III started Milestone: Start Phase III (4Q17) Julian Zhu dasiglucagon in rescue pen Zealand...
BioCentury | Jul 7, 2017
Financial News

Zealand planning NASDAQ listing

...Phase II trial in the indication. Zealand gained DKK1.50 to DKK135 in Copenhagen on Friday. Paul Bonanos Adlyxin dasiglucagon in rescue pen glepaglutide lixisenatide Lyxumia Soliqua Suliqua Zealand...
BioCentury | Sep 5, 2016
Clinical News

Dasiglucagon in rescue pen: Phase II data

...treatment arms. Dasiglucagon was well tolerated. Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: Dasiglucagon in rescue pen (formerly ZP4207 in rescue pen...
BioCentury | Feb 15, 2016
Clinical News

ZP4207 in rescue pen: Phase II started

...Type I diabetics after an insulin-induced hypoglycemia event. Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: ZP4207 in rescue pen...
BioCentury | Jul 13, 2015
Clinical News

ZP4207 in rescue pen: Phase I data

...mild to moderate hypoglycemia are expected this half. Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: ZP4207 in rescue pen...
Items per page:
1 - 10 of 10